视神经炎
医学
视力
眼科
视神经
多发性硬化
甲基强的松龙
外科
精神科
作者
Julie Rode,Julie Pique,Adil Maarouf,Xavier Ayrignac,Bertrand Bourre,Jonathan Ciron,Mikaël Cohen,Nicolas Collongues,Romain Deschamps,Élisabeth Maillart,Alexis Montcuquet,Caroline Papeix,Aurélie Ruet,Sandrine Wiertlewski,Hélène Zéphir,Romain Marignier,Bertrand Audoin
标识
DOI:10.1136/jnnp-2022-330360
摘要
Background To characterise the response to treatment of inaugural optic neuritis (ON) in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Methods We searched the French MOGAD database for adults with inaugural ON with a detailed report of acute treatment modalities and measures of high-contrast best-corrected visual acuity (BCVA) at nadir and after 3 months. Predictors of visual outcomes were assessed by multivariable analysis. Results Among 245 patients with at least one episode of ON, 82 fulfilled all criteria, and data on the peripapillary retinal nerve fibre layer (pRNFL) were available for 44. All patients received methylprednisolone (MP), combined with plasma exchange in 18. After 3 months, 75 of 82 (91%) patients retained full BCVA recovery, and median (range) pRNFL of the affected eye was 72 µm (40–102). Failure to regain 0.0 logarithmic minimum angle of resolution vision (Snellen 20/20) at 3 months was associated with time to first MP treatment ≥10 days (OR 16, 95% CI 1.14 to 213, p=0.01). pRNFL thickness after 3 months was related to better BCVA at nadir and time to first MP treatment <10 days (r2=19%, p=0.004 and r2=11%, p=0.03, respectively). Conclusions Time to MP affects functional but also structural visual outcomes of ON in MOGAD.
科研通智能强力驱动
Strongly Powered by AbleSci AI